There are about 11 more trading days between now and Sept.

New Post Public Reply Private Reply Replies (3) Message Board
Daveludlow
There are about 11 more trading days between now and Sept. 1st or 2nd when the CC is, where I assume Gerald will give us LymPro revenue guidance. He also told us we would be getting the LymPro partnership agreement by the end of summer.(End of August, or officially Sept. 20th) The LymPro "bridge data" could come out any time, as well.

AMBS' pps is pretty dependent on LymPro news. Why? Because LymPro news leads to revenue in a few months, which is what Wall Street cares about. They don't get off that much on pre-clincial stuff. So unless MANF delivers significant news (Partnerships, which are unlikely this year) it is not going to help us much. I know a lot of people think we are all about MANF, and we will be in a couple of years, but right now WE ARE ALL ABOUT LYMPRO!! No one knows what to make of Eltoprazine and management hasn't donw anything to change that. They could at some point, but haven't yet.

LymPro holds the key to our financial salvation in the next 6 months! If Gerald plays his cards right, LymPro alone could take us into the .30 to .60 cent range, where we could do a reasonable RS, up list, and away we'd go!

Does Gerald know how to play his cards right? Well, he has been successful in many areas with AMBS, especially advancing the science and assembling talent. Pardon me for another analogy, but he reminds me of a talented running back who can run, block, and catch the ball. He has it all. The only weakness, and I hate to even bring it up, because it's nit picking. He has a very slight tendency...to fumble the ball in the red zone!! On three occasions this year when the pps was gaining momentum around Conference times, once at .138 cents, once at.173 cents, & once at .193 cents, Gerald has made announcements that caused the pps ball to squirt out of his hands and tumble to the ground. As a result, we are trading at .10 cents, precariously!

But that is in the past, we've covered that and it isn't relevant now. Our expectations are focused on the CC and the shareholder meeting. I suspect we will experience a run....at some point soon.

My advice to Aimee, to give to Gerald, is to know what the expectations are that have been built up in the shareholders and manage them before you release news. If shareholders are expecting "bridge data" in the 90s for spec & sens, but the data is only in the high 80s....do some expectation damage control ahead of time. Or, if shareholders are expecting our LymPro Partner to be Johnson & Johnson and get 30 million from them up front in cash; do some expectation damage control if our CLIA partner is Acne Labs of Cleveland, and we're paying them instead of them paying us. You know? This is not rocket science. The stuff your scientists do curing diseases is what's like rocket science, not managing shareholder expectations.

Just have Aimee, AMBS' IR person, watch the message boards and keep abreast of what the expectations are so you can address them subtly in a tweet or blog or something - if you think they are out of line. That way you prevent massive sell offs and disillusioned shareholders.

We're in the 4th quarter and we're a little behind.We're backed up to our 20 yard line and have another 60 yards to go before we get into the red zone. OK Gerald, you've assembled a "dream team," now lets execute! This is the Super Bowl!!!

Amarantus Bioscience Holdings (AMBS) Stock Research Links

AMBS Board Company Profile Buy Rating Time & Sales News Filings Financials
Scroll down for more posts ▼

Top 10 Most Recent News Articles

CARsgen's CAR-T Breakthrough on China's Insurance List

Updated Category News Views 254

A Game Changer for CAR-T Therapies There's a breeze of optimism blowing from Shanghai these days—a rare sensation in this market of endless skirmishes. CARsgen Therapeutics Holdings Limited, a company entrenched in the development of cutting-edge CAR T-cell therapies, just notched a victory. They've announced that their CAR T-cell therapy product, satricabtagene...

Continue Reading
HONGQI's EHS4 Launch in Europe: Bridging East and West

Updated Category News Views 127

Revving Up a New Chapter: HONGQI in Venice There's a new player in the European automotive scene, and it's rolling in with more style than a Venetian gondola. HONGQI, a name that's been turning gears in China since '58, is packing its suitcases full of Eastern elegance and landing straight in Venice with the all-electric EHS4. On November 16, the brand is set to unveil...

Continue Reading
Beko Pushes for Policy Synergy Amidst Carbon Shakeup

Updated Category News Views 190

When big names like Beko step up on the global stage, you pay attention. During the COP31 panels in Antalya, Türkiye, the company's brass made one thing clear: we need harmony in how climate, trade, and finance policies come together. The stakes? The very strength of industrial competitiveness as new carbon rules turn the heat up on manufacturing practices. The Call for...

Continue Reading
MV Transportation Celebrates Leadership Nomination for FTA

Updated Category News Views 192

MV Throws Support Behind Aesch for FTA Role In this wild world where public transit feels the heat from financial burdens, MV Transportation's recent move to support Mark Aesch for the Federal Transit Administration's top spot isn’t just a nod of approval—it's a full-blown trumpet blast. They're not just doling out a basic endorsement here; they're practically waving...

Continue Reading
Fluence Energy Faces Leadership Departures Amid Legal Woes

Updated Category News Views 155

Fluence Energy's Rocky Road Continues It's chaos once again in the halls of Fluence Energy (NASDAQ:FLNC). The ship seems to drift further from solid ground as their CEO and CFO candidly decided to jump ship, shaking investor confidence even more vigorously. The market's reaction was swift and brutal: a nasty 9% share drop, leaving investors with more than just a headache....

Continue Reading
HiTHIUM Joins Cambridge to Boost Global Energy Storage

Updated Category News Views 410

HiTHIUM and Cambridge's New Energy Venture There's a big splash coming out of Xiamen, folks. HiTHIUM, a heavyweight in the energy storage sector, has decided to team up with the University of Cambridge. They inked a deal aiming to bridge the academic ivory tower with industrial grit, focusing on long-duration energy storage. It was all sealed during the Global Energy...

Continue Reading
WeaveGrid Powers EVConnectNC: Charging Incentives Launched

Updated Category News Views 139

Transforming Utilities with EVConnectNC In a fresh move by WeaveGrid, North Carolina's Electric Cooperatives have teamed up to roll out EVConnectNC. This innovative program aims to manage the burgeoning demand for electric vehicle (EV) charging in rural and suburban areas under North Carolina's cooperative umbrella. Think of it as a smart way to handle new loads without...

Continue Reading
AppLovin Legal Woes: A Deep Dive into Investor Claims

Updated Category News Views 186

AppLovin Faces Legal Heat and Market Scrutiny Bitter truth has a way of crashing like a wave, and AppLovin (NASDAQ: APP) is feeling the brunt of it. Now knee-deep in a securities class action, the firm’s been accused of selling fairy tales about its AI capabilities, leaving investors clutching at substantial losses. If you’ve been banking on their promises between...

Continue Reading
EZaccessMD Data Breach: Class Action Lawsuit Looms

Updated Category News Views 143

Data breaches are the bogeyman no one wants lurking in the shadows, and when it’s your personal info at stake, folks rightfully squirm. This recent fiasco at EZaccessMD is one of those unsettling incidents. The word on the street isn't pretty: sensitive medical data has slipped through the cracks, leaving Edelson Lechtzin LLP, a heavyweight in class action maneuvers, to...

Continue Reading
Breakthrough T1D Pushes Global T1D Awareness Forward

Updated Category News Views 155

Shining a Light on T1D with Global Efforts In a world where a change in lifestyle can happen at the drop of a hat, Breakthrough T1D is making waves by expanding their global "See T1D" campaign in honor of World Diabetes Day. This isn't your run-of-the-mill awareness push—this is about propelling an understanding of what life truly entails for those living with type 1...

Continue Reading

Top 5 Most Recently Viewed Articles

Class Action Lawsuit Against Joint Stock Company Kaspi.kz (KSPI)

Updated Category News Views 149

Understanding the Class Action Lawsuit Against Joint Stock Company Kaspi.kz Levi & Korsinsky, LLP has brought to light an important class action lawsuit concerning the Joint Stock Company Kaspi.kz (NASDAQ: KSPI). This initiative aims to provide legal recourse to investors who may have suffered due to alleged fraudulent activities that negatively impacted the company's...

Continue Reading
Verdafero Enhances Emission Reporting for Hospitality Sector

Updated Category News Views 133

Verdafero Launches New Emissions Reporting Service Verdafero, a prominent player in sustainability solutions, has introduced an expanded service for emissions reporting that now includes comprehensive tracking and analysis of Scope 1, Scope 2, and Scope 3 emissions specifically for the hospitality industry. This innovative offering provides businesses in this sector with...

Continue Reading
Analyst Ratings Spark Interest in GE Vernova and Peers

Updated Category News Views 187

Key Analyst Ratings for Prominent Stocks Wall Street analysts have recently begun covering some noteworthy companies, aiming to provide insights for potential investors. Analyst ratings can spark interest in stocks and guide buying decisions, especially when backed by thorough research. This article highlights the initiation of coverage on five significant stocks,...

Continue Reading
Repertoire Immune Medicines and Lilly Team Up on New Therapies

Updated Category News Views 210

Repertoire Immune Medicines and Eli Lilly Announce Collaboration Repertoire Immune Medicines is excited to announce a significant strategic collaboration with Eli Lilly and Company, focusing on the development of tolerizing therapies to treat various autoimmune diseases. This partnership is set to leverage Repertoire's advanced DECODE™ platform, designed to pioneer T...

Continue Reading
Manhattan Associates Faces Lawsuit Amid Significant Losses

Updated Category News Views 1108

Manhattan Associates Faces Lawsuit Amid Significant Losses A class action lawsuit has emerged against Manhattan Associates, Inc. (NASDAQ: MANH), a prominent player in software solutions for supply chain management and inventory operations. This legal action highlights concerns from investors who have experienced notable financial losses stemming from alleged...

Continue Reading